TNFi-IR | |
Patient demographics | |
Age | Mean ages were similar across the patient populations, ranging from 50.94 years (RADIATE) to 58.2 years (ORAL Step) |
Sex | The majority of patients were female |
Ethnicity | In those trials reporting ethnicity, the majority of the patients were Caucasian |
Patient baseline clinical status | |
Weight | Two studies reported mean weight from 78.2 kg (ATTAIN) to 79.4 kg (TARGET) |
Proportion rheumatoid factor positive | The proportion of patients who were rheumatoid factor positive varied from 51% (Manders 2014) to 79% (TARGET, RADIATE and REFLEX) |
Disease duration | Mean disease duration ranged from 5.6 years (Manders 2014) to 14.0 years46 (RA-BEACON) |
Tender joint count | Mean tender joint count ranged from 27.6 (ORAL step) to 33.9 (REFLEX) |
Swollen joint count | Mean swollen joint count ranged from 6 (RA-BEACON) to 23.4 (REFLEX) |
Prior DMARD use | In the two studies (REFLEX and RADIATE) reporting prior csDMARD use, the use varied from 1.9 (RADIATE) to 2.6 (REFLEX) |
Baseline disease severity | Mean DAS28 differed between the studies. For the csDMARD or methotrexate arms, the mean baseline DAS28-CRP ranged from 5.4 (ORAL Step) to 6.9 (REFLEX); the DAS28-ESR from 4.7 (Manders et al 2015) to 6.5 (ORAL Step) and the DAS28-unspecified from 6.5 (ATTAIN) to 6.8 (RADIATE) |
CRP, C reactive protein; csDMARD, conventional disease-modifying antirheumatic drugs;DAS-28, Disease Activity Score 28-joint count; ESR, erythrocyte sedimentation rate; IR, inadequate response; TNF, tumour necrosis factor inhibitor.